Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||GC1118||Phase I||Actionable||In a Phase I clinical trial, treatment with GC1118 resulted in no responses, but stable disease in 58% (7/12), and a median progression-free survival (PFS) of 14 weeks in patients with metastatic colorectal cancer with no prior anti-EGFR therapy, and resulted in an overall response rate of 17% (2/12; all partial responses), stable disease in 8% (1/12), and median PFS of 6.9 weeks in patients with metastatic colorectal cancer with resistance to anti-EGFR therapy (PMID: 31164456; NCT02352571).||31164456|